| Outcome Measures: |
Primary: Change from baseline in glycosylated hemoglobin., Final Visit. | Secondary: Change from baseline in glycosylated hemoglobin., Weeks 4, 8, 12, 16 and 20|Change from baseline in fasting plasma glucose., Weeks 2, 4, 8, 12, 16, 20 and Final Visit|Change from baseline in serum insulin., Weeks 4, 12, 16, 20 and Final Visit.|Change from baseline in C-peptide., Weeks 4, 12, 16, 20 and Final Visit.|Change from baseline in triglycerides., Weeks 12, 16, 20 and Final Visit.|Change from baseline in total cholesterol., Weeks 12, 16, 20 and Final Visit.|Change from baseline in high-density lipoprotein., Weeks 12, 16, 20 and Final Visit.|Change from baseline in low-density lipoprotein., Weeks 12, 16, 20 and Final Visit.|Change from baseline in very-low-density lipoprotein., Weeks 12, 16, 20 and Final Visit.|Change from base line in apolipoproteins A1 and B 100., Final Visit|Change from baseline in free fatty acids., Weeks 12, 16, 20 and Final Visit.|Change from baseline in thrombosis marker (plasminogen activator inhibitor-1), Weeks 4, 12, 16, 20 and Final Visit|Change from baseline in thrombosis marker (fibrinogen), Weeks 4, 12, 16, 20 and Final Visit|Change from baseline in inflammation marker (Interleukin-6)., Weeks 4, 12, 16, 20 and Final Visit|Change from baseline in inflammation marker (C-reactive protein)., Weeks 4, 12, 16, 20, and Final Visit|Change from baseline in urinary albumin to creatinine ratio., Weeks 12, 16, 20 and Final Visit
|
